Ramipril — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hypertension

• Amlodipine
• Atenolol
• Bisoprolol
• Carvedilol
• Diltiazem
• Furosemide
• Hydrochlorothiazide
• Lisinopril

Other medications in Heart & Cardiovascular

• Ranolazine
• Riociguat
• Rivaroxaban
• Rosuvastatin
• Sacubitril-Valsartan
• Selexipag
• Sildenafil (PAH)
• Simvastatin

What Ramipril is approved for (FDA label)

Ramipril capsules are an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics (1.1) . In patients 55 years or older at high risk of developing a major cardiovascular event, ramipril capsules are indicated to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes ( 1.2 ). Ramipril capsules are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction (1.3) . 1.1 Hypertension Ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure.

Source: Read the full FDA label on DailyMed. Label effective date: September 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ramipril (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ramipril as soon as possible [see Warnings and Precautions (5.6) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.6) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning When pregnancy is detected, discontinue ramipril as soon as possible (5.6) . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.6) .

Source: FDA prescribing information (DailyMed). Set ID: 45707435-4fc8-457e-9ff2-02d7be9b4a6e. SPL document ID: 5aa8efd9-6e26-311d-e063-6394a90afe25. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ramipril (FDA label)

Ramipril is supplied as hard gelatin capsules containing 1.25 mg, 2.5 mg, 5 mg, and 10 mg of ramipril. Ramipril Capsules USP, 1.25 mg are yellow/yellow size ‘4’ hard gelatin capsules imprinted with ‘D’ on yellow cap and ‘05’ on yellow body with black edible ink filled with white to almost white powder. Ramipril Capsules USP, 2.5 mg are orange/orange size ‘4’ hard gelatin capsules imprinted with ‘D’ on orange cap and ‘06’ on orange body with black edible ink filled with white to almost white powder.

Source: FDA prescribing information (DailyMed). Set ID: 45707435-4fc8-457e-9ff2-02d7be9b4a6e. SPL document ID: 5aa8efd9-6e26-311d-e063-6394a90afe25. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ramipril (FDA label)

The most common adverse reactions in patients with hypertension included headache, dizziness, fatigue, and cough (6.1) .To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension Ramipril has been evaluated for safety in over 4000 patients with hypertension; of these, 1230 patients were studied in U.S. controlled trials, and 1107 were studied in foreign controlled trials.

Source: FDA prescribing information (DailyMed). Set ID: 45707435-4fc8-457e-9ff2-02d7be9b4a6e. SPL document ID: 5aa8efd9-6e26-311d-e063-6394a90afe25. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ramipril (FDA label)

Ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). Ramipril capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer ramipril capsules within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.1) ] . Do not co-administer ramipril capsules with aliskiren: • in patients with diabetes Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema (4) . Ramipril capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer ramipril capsules within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor ( 4 ). Do not co-administer aliskiren with ramipril capsules in patients with diabetes (4) .

Source: FDA prescribing information (DailyMed). Set ID: 45707435-4fc8-457e-9ff2-02d7be9b4a6e. SPL document ID: 5aa8efd9-6e26-311d-e063-6394a90afe25. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ramipril (FDA label)

Angioedema, increased risk in patients with a prior history (5.1) Hypotension and hyperkalemia (5.5, 5.8) Renal impairment: monitor renal function during therapy (5.3) Avoid concomitant use of an ACE inhibitor and angiotensin blocker (5.7) Rare cholestatic jaundice and hepatic failure (5.2) Rare neutropenia and agranulocytosis (5.4) 5.1 Anaphylactoid and Possibly Related Reactions Presumably because drugs that act directly on the renin-angiotensin-aldosterone system (e.g., ACE inhibitors) affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving these drugs (including ramipril) may be subject to a variety of adverse reactions, some of them serious. Angioedema Angioedema may occur at any time during treatment with ACE inhibitors including ramipril. Head and Neck Angioedema Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor.

Source: FDA prescribing information (DailyMed). Set ID: 45707435-4fc8-457e-9ff2-02d7be9b4a6e. SPL document ID: 5aa8efd9-6e26-311d-e063-6394a90afe25. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ramipril (FDA label)

Diuretics: Possibility of excessive hypotension ( 7.1 ). Lithium: Use with caution (7.4) . Gold: Nitritoid reactions have been reported ( 7.5 ). NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.6 ). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk ( 7.7 ) 7.1 Diuretics Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, reduce the starting dose [see Dosage and Administration (2) ] . 7.2 Agents Increasing Serum Potassium Coadministration of ramipril with other drugs that raise serum potassium levels may result in hyperkalemia.

Source: FDA prescribing information (DailyMed). Set ID: 45707435-4fc8-457e-9ff2-02d7be9b4a6e. SPL document ID: 5aa8efd9-6e26-311d-e063-6394a90afe25. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.